David H. Wesorick, MD; Vineet Chopra, MD, MSc
Disclosures: Dr. Chopra reports grants from the Agency for Healthcare Research and Quality. Dr. Wesorick has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-1400.
By illustrating that the rate of antibiotic prescription is the primary factor associated with the incidence of C difficile infection, this study provides strong support for the role of antibiotic stewardship to prevent these infections in both acute and long-term care settings.
Because many infections in long-term care facilities originate in hospitals, stringent attention to infection prevention measures, including contact isolation precautions and hand hygiene, are needed in long-term care settings.
Excessively strict “confidentiality” clauses that bar physicians from discussing anything about their work or employer could allow hospitals to hide quality and safety concerns and undermine a physician's ability to uncover and fix problems.
Physicians should be aware of “termination without cause” clauses that allow employers to fire physicians for almost any reason and “noncompete” clauses that make it difficult for physicians to leave their current employers.
Individual physicians often lack the insight or influence to challenge these clauses, raising concerns about how physicians will preserve their professional integrity in the face of the commercial practice of medicine.
Definitive gout diagnosis requires the identification of monosodium urate crystals in fluid sampled from the joint or tophus.
Elevated serum urate levels are not diagnostic of gout. Hyperuricemia is approximately 5 times more common than gout itself.
Gout may mimic septic arthritis and lead to delayed or missed diagnosis. In addition, septic arthritis can occur concomitantly with gout. Early arthrocentesis and crystal evaluation are essential to diagnosis.
Acute attacks of gout should be treated with colchicine, NSAIDs, or glucocorticoids (systemic or intra-articular) and continued for 7 to 10 days to avoid rebound attacks.
Urate-lowering therapy should be continued during the treatment of acute gout.
These results question the association between DPP-4 inhibitors and heart failure hospitalizations reported in early postmarketing trials.
This study highlights the FDA's Mini-Sentinel System, a large, multipayer, drug safety database that facilitated this robust and timely assessment of DPP-4 inhibitors. An accompanying editorial highlights the value of the Mini-Sentinel System for examining issues of drug safety.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Wesorick DH, Chopra V. Annals for Hospitalists - 19 July 2016. Ann Intern Med. 2016;165:HO1. doi: 10.7326/AFHO201607190
Download citation file:
Published: Ann Intern Med. 2016;165(2):HO1.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use